June 30, 2004 - New drug to prevent lasting brain damage
Pharmos is focused on helping people think more clearly -- with cannabis. The biotechnology company is developing cannabis-related compounds that don't have psychotropic effects as potential treatments for central nervous system disorders. Pharmos' lead drug candidate, dexanabinol, is a neuroprotective compound that could prevent lasting damage from traumatic brain injury. It has received FDA fast track status for this indication. The drug candidate may also limit post-surgery memory loss and cognitive impairment. Other targets for these compounds include stroke, neuropathic pain, multiple sclerosis, and Alzheimer's disease.
|
The above is not legal advice. That can only come from a qualified attorney
who is familiar with all the facts and circumstances of a particular, specific
case and the relevant law. See Terms
of Use.
|
